| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |




From the Department of Pathology
and the Laboratory of Thymus Research, Department of Immunology,* Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; the Laboratory of Experimental Oncology,
Faculty of Medicine, University of São Paulo, São Paulo, Brazil; the Division of Immunogenetics,
Hospital de Clínicas "José de San Martín," Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina; and the Department of Dermatology,¶ University of California, Los Angeles, California
| Abstract |
|---|
|
|
|---|
The cortical population of thymic nurse cells (TNCs), lymphoepithelial complexes in which immature thymocytes undergo differentiation and occasionally die by apoptosis, is altered after infection. Specifically, in vitro analysis of TNCs recovered from the thymus of infected mice showed that they are smaller in both size and number, have altered expression of ECM molecules,and release thymocytes faster than those from control animals.8 In this regard, alterations in cell-cell and cell-ECM interactions in the thymic microenvironment after T. cruzi infection are accompanied by high numbers of immature CD4+CD8+ T cells found in lymph nodes of infected mice. Interestingly, some of these lymphocytes bear potentially autoreactive T-cell receptors (TCRs), probably representing cells that escaped from the normal processes of thymic selection.9 The presence of these immature T cells in the periphery might contribute to the induction of chagasic cardiopathy through an autoimmune response.
Galectins are a family of ß-galactoside-binding proteins highly conserved throughout animal evolution, which are present at different subcellular compartments.10 These proteins modulate several biological processes, such as cell adhesion, migration, proliferation, and apoptosis.11 Galectin-1, -3, and -9 are expressed in thymus, among which galectin-1 and -3 are present throughout all of the thymic parenchyma, being mainly produced by thymic epithelial cells (TECs).12-15 Interestingly, recent evidence indicates that galectins can interact with ECM glycoproteins and modulate cell-cell interactions within the thymic microenvironment.12,15 We have demonstrated that galectin-3 produced by thymic stromal cells can interfere with TEC/thymocyte adhesion, by acting as an anti-adhesive molecule and modulating protein-carbohydrate interactions.15
It has become increasingly apparent that galectin-1 and -3 function as regulatory proteins, sometimes with opposite effects. Galectin-1 can induce apoptosis in immature thymocytes displaying the CD3lowCD4CD8 and CD3lowCD4lowCD8low phenotypes, an effect that parallels the processes of selection and thymocyte differentiation.12,16 On the other hand, in vitro studies revealed that intracellular galectin-3 inhibits apoptosis induced by a wide variety of stimuli in activated T lymphocytes and tumor cells,17,18 whereas extracellular galectin-3 promotes apoptosis when added exogenously to T cells.19,20 Interestingly, recent data suggest that galectin-1 and -3 kill T cells by binding to them and engaging different cell surface glycoproteins.20 In addition, these carbohydrate-binding proteins can trigger different cell death pathways, with or without caspase activation, in different cell types.21-23
Despite the increasing understanding of the effects of T. cruzi infection on thymus physiology, the mechanisms that control CD4+CD8+ cell depletion and the escape of immature thymocytes from the infected thymus remain unclear. In the present study, we have found evidence of a critical role of galectin-3 in thymic atrophy during the acute phase of T. cruzi infection. Combining in vitro and in vivo assays conducted in control and infected galectin-3-null mice, we found a clear association of this protein with physiological processes linked to thymocyte depletion, including increased susceptibility of cells to cell death and enhanced ability of cells to migrate away from the thymus.
| Materials and Methods |
|---|
|
|
|---|
Male BALB/c mice (5 to 8 weeks old) were used in most experiments. Gal-3/ mice in BALB/c and C57BL/6 genetic backgrounds were generated as previously described.24 These mice were housed and cared for at the Animal Facilities of the Oswaldo Cruz Foundation (Rio de Janeiro, Brazil). Blood-derived Trypanosoma cruzi parasites (Colombian strain) were obtained from previously infected BALB/c mice. Trypomastigotes (n = 105) were inoculated intraperitoneally into mice. Mice were bled and sacrificed 18 and 21 days after infection. For selected in vitro experiments, parasites were also obtained from infected cultures of the VERO cell line.5 Animals were handled according to the guidelines approved by the Oswaldo Cruz Foundation Ethics Committee for animal research.
Reagents
The apoptosis detection kit and murine recombinant galectin-1 and -3 were obtained from R&D Systems (Minneapolis, MN). Fetal bovine serum and culture medium were purchased from Hyclone Laboratories (South Logan, UT). Penicillin and streptomycin were obtained from Life Technologies, Inc. (Gaithersburg, MD), whereas collagenase A, dispase, and DNase I were from Boehringer-Mannheim (Mannheim, Germany). Formaldehyde and paraformaldehyde were from Merck (Rio de Janeiro, Brazil). All other reagents were purchased from Sigma (St. Louis, MO), except those used for Northern blotting (below).
Antibodies
Rabbit anti-galectin-1 immune serum was obtained as described.11 Goat anti-human galectin-1 antibody was purchased from R&D Systems. Anti-CD8/Cy-chrome, anti-CD4/phycoerithrin (PE), and mouse anti-human galectin-3 (clone B2C10) monoclonal antibodies (mAb) were purchased from Pharmingen/Becton Dickinson (San Diego, CA). Biotinylated rat anti-mouse galectin-3 mAb (clone M3/38) was purchased from Cedarlane Laboratories (Hornby, ON, Canada). Fluorescein isothiocyanate-conjugated goat anti-rabbit IgG was from Biosys (Compiègne, France). Anti-mouse laminin and fibronectin sera were obtained from Novotec (St. Martin-La-Garenne, France). Rabbit pan anti-cytokeratin was obtained from Sigma. Alexa 543-conjugated goat anti-mouse IgG, Alexa 488-conjugated goat anti-rabbit IgG, and Alexa 633-conjugated streptavidin were purchased from Molecular Probes (Eugene, OR). Rhodamine-conjugated anti-goat IgG was from Santa Cruz Biotechnology (Santa Cruz, CA).
Tissues and Cell Cultures
Thymuses were obtained from either control or infected BALB/c mice at the peak of parasitemia and immediately frozen in liquid nitrogen. The thymic epithelial cell line IT-76M1 was provided by Dr. T. Itoh (Tohoku University, Sendai, Japan) and cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mmol/L L-glutamine, 50 µmol/L 2-mercaptoethanol, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO2. For in vitro infections, IT-76M1 cells were plated onto sterile glass slides (105 cells/slide) and cultured for 24 hours. Parasites obtained from infected VERO cultures were added to these cells, in a ratio of 50 parasites/cell, for an additional period of 48 hours. Cultures were then fixed in 4% buffered paraformaldehyde for 5 minutes and processed for immunocytochemistry. TNCs, isolated from thymuses of control or infected mice as previously described,25,26 were plated onto sterile glass slides and cultured for 35 to 60 hours. Adhered TNCs were then washed with phosphate-buffered saline (PBS), fixed as mentioned above and processed for immunocytochemistry.
Immunofluorescence and Flow Cytometry
Cryostat sections (5 µm) were prepared from frozen thymuses and then fixed with cold acetone for further processing, essentially as described elsewhere.5 Paraformaldehyde-fixed TNC cultures and the TEC line were subjected to immunofluorescence as described.27 Staining with appropriate dilutions of anti-galectin-1 or anti-galectin-3 antibodies was performed for 1 hour, followed by incubation with the corresponding secondary antibodies. For double labeling, additional incubations with rabbit anti-laminin or anti-fibronectin anti-sera were performed. The samples were analyzed using a laser confocal microscope (LSM 410; Zeiss, Jena, Germany).
To characterize the presence of galectins on thymocyte surface, living cells obtained by mechanical tearing of the thymus were labeled with anti-galectin-1 sera or biotinylated anti-galectin-3 mAb for 1 hour, followed by the appropriate secondary Ab and then incubated with an anti-CD4-PE plus anti-CD8-Cy for 40 minutes, washed, and fixed in 1% formaldehyde. To evaluate the intracellular expression of galectin-1 and galectin-3, the thymocytes were labeled with anti-CD4-PE plus anti-CD8-Cy for 40 minutes, washed and fixed in 1% formaldehyde. Then, the cells were washed with PBS/bovine serum albumin 0.5%, permeabilized with PBS/saponin 0.05% for 20 minutes, labeled with anti-galectin-1 and biotinylated anti-galectin-3 for 40 minutes and followed by the appropriate secondary Ab. Samples were immediately analyzed using a flow cytometer (FACScalibur, Becton Dickinson). A minimum of 10,000 up to 500,000 cells were analyzed depending on the type of assay.
Northern Blotting
Murine galectin-1 and human galectin-3 cDNA were generated by the reverse transcription-polymerase chain reaction (RT-PCR). The primers used were 5'-TCTCAAACCTGGGGAATGTC-3' (sense) and 5'-CTTGATGGTCAGGTCAGC-3' (anti-sense) for galectin-1 and 5'-CCTGGAGCTTATCCTGGTCA-3' (sense) and 5'-GTCACCACTGATCCCCAGTT-3' (anti-sense) for galectin-3.
Cell Adhesion Assay
The TEC line was plated onto eight-well culture chambers (Nunc, Rochester, NY) at a ratio of 104 cells/well for 24 hours. Before each experiment, TECs were treated for 30 minutes with an anti-galectin-3 mAb or control Ig. Thymocytes were then allowed to adhere to TEC cultures (50 thymocytes/TEC) for 1 hour. Nonadherent cells were gently washed out with PBS, and the remaining cells were subsequently fixed in ethanol and stained with Giemsa (Merck). The number of adhered thymocytes per TEC was then determined by direct counting. Data were expressed as an association index,28
calculated as follows:
![]() |
Evaluation of Thymocyte Release from TNC Complexes
Freshly isolated TNC complexes were plated onto flat-bottom 96-well tissue culture dishes (7.5 x 103 TNCs/well) and cultured for 24 hours. After this period, these cells were treated with mouse recombinant galectin-3 at 5 µg/ml (R&D Systems). To investigate the role of carbohydrate recognition in galectin-3-mediated thymocyte release, cells were treated with galectin-3 plus lactose or melibiose (10 mmol/L). Controls included cells treated with bovine serum albumin (5 µg/ml) or untreated cultures. After 12 hours of incubation, TNCs were fixed in methanol for 5 minutes, labeled with Toluidine blue (0.05% in water). The dye was then solubilized in a fixed volume of ethanol, and the absorbance of the solution was determined using a spectrophotometer (595 nm). Absorbance values were used as an estimation of thymocyte release in cell cultures.
Thymocyte Migration Assay
Transwell membranes (Costar, New York, NY) were treated with 10 µg/ml laminin (Sigma) for 2 hours and then blocked with 0.5% bovine serum albumin for 30 minutes. Thymocytes were incubated with mouse recombinant galectin-1 (1 µg/ml) or galectin-3 (5 µg/ml) for 30 minutes at 37°C. Alternatively, galectin-1 or -3 was incubated with 0.1 mol/L lactose for 30 minutes at 37°C and applied to the cells. Treated thymocytes were added to the upper chamber of the transwell device, at a ratio of 2.5 x 106 cells/chamber, and allowed to migrate for 4 hours. Cells that migrated through the membranes were counted. The phenotype of both migrating and nonmigrating cells was determined by flow cytometry as described above.
Cell Death Assay
Thymocytes obtained from both C57BL/6 wild-type and gal-3/ mice were treated with mouse recombinant galectin-3 (50 µg/ml). Alternatively, galectin-3 plus 0.1 mol/L lactose was applied to the cells. Thymocytes treated with 100 nmol/L hydrocortisone hemisuccinate sodium were used as a positive control for apoptosis. After 12 hours, thymocytes were then recovered and labeled with annexin V and propidium iodide using the Annexin V detection kit, according to the protocol suggested by the manufacturer (R&D Systems), and analyzed by flow cytometry.
Statistical Analysis
The one-way analysis of variance and the Newman-Keuls post test were used for comparison purposes. P values less than 0.05 were considered statistically significant.
| Results |
|---|
|
|
|---|
Since recent evidence indicates the presence of galectin-1 and -3 in TECs,12,13,15
we first investigated the expression and localization of these proteins in the thymus of control and infected mice. Although galectin-1 was detected throughout all of the thymic cortex and medulla (Figure 1A)
, galectin-3 was predominantly found in the medulla and in scattered cells in the cortex (Figure 1C)
. After T. cruzi infection, thymic atrophy was accompanied by a striking accumulation of galectin-3 in both the medulla and the cortex (Figure 1D)
, an effect that was associated with de novo expression of galectin-3, as judged by Northern blot analysis (Figure 1G
, middle). In contrast, galectin-1 staining profile remained unchanged on infection (Figure 1B)
, and there was a slight decrease in the mRNA levels (Figure 1G
, left).
|
The next issue we addressed was the modulation of these endogenous lectins in cellular models resembling the thymic microenvironment, namely TEC lines and TNCs. Although IT-76M1 cells did not express galectin-1 (data not shown), this TEC line expressed substantial amounts of galectin-3, and its expression was up-regulated after in vitro T. cruzi infection (Figure 2, A and B)
. Furthermore, TNCs expressed low levels of galectin-1, and its expression was not modulated after infection (Figure 2, C and D)
, whereas galectin-3 expression increased in infected TNCs (Figure 2F)
. These results were similar to those found in the normal and infected thymus, indicating that comparable mechanisms may be operating regarding the control of galectin-1 and -3 expression in models resembling the thymic epithelial microenvironment. These data demonstrate that the expression of galectin-3 is up-regulated in thymus from T. cruzi infected mice and suggest that the main cellular component involved in this modulation is represented by thymic epithelial cells although the participation of thymocytes in this process cannot be discarded.
|
|
We have previously demonstrated that, on acute T. cruzi infection, a striking thymic atrophy takes place in different mouse strains.5 The C57BL/6 mice are resistant to T. cruzi infection, when compared to BALB/c mice. Both mouse strains show a parasitemia peak within 21 days after infection. However, few C57BL/6 mice die from infection, whereas BALB/c mice show high mortality. Interestingly, gal-3/ mice of both genetic backgrounds showed higher susceptibility to infection, exhibiting a parasitemia peak within 16 to 18 days and a 100% mortality rate (data not shown).
Interestingly, wild-type T. cruzi-infected mice of both C57BL/6 and BALB/c genetic backgrounds exhibited significant thymocyte depletion (absolute number of thymocytes) when compared to the respective control mice. Strikingly, this difference was not apparent between control and infected gal-3/ mice. When thymocyte subsets from infected wild-type animals were analyzed by flow cytometry, a significant decrease in the relative amounts of CD4+CD8+ double-positive cells, together with an increase of either CD4+ and CD8+ single-positive cells, was observed, as shown in Figure 4A
(top) for BALB/c mice. This observation could be attributable to the CD4+CD8+ double-positive cell depletion during infection, because no significant changes in absolute cell number of CD4+ or CD8+ single-positive cells were detected between thymus from control and infected mice. Interestingly, when gal-3/ mice were infected, the expected depletion of CD4+CD8+ double-positive cells did not occur (Figure 4A
, bottom).
|
|
Taken together, these results suggest that the accumulation of galectin-3 in the thymus of infected mice may be associated with the depletion of CD4+CD8+ thymocytes. This observation prompted us to investigate whether the exposure of thymocytes to galectin-3 would induce thymocyte death. No significant differences were observed regarding spontaneous cell death during the course of the experiments (Figure 4B)
. However, treatment of thymocytes from either wild-type or gal-3/ mice with galectin-3 for 12 hours induced cell apoptosis, an effect that was inhibited by 0.1 mol/L lactose. Interestingly, thymocytes treated with galectin-3 showed a significant increase in the frequency of cells stained with propidium iodide. As a positive control of thymocyte death, cells were also treated with hydrocortisone (Figure 4B)
. Thymocytes from gal-3/ mice showed resistance to hydrocortisone-and galectin-3-induced cell death as compared to wild-type mice, suggesting that the presence of galectin-3 may increase their susceptibility to cell death. These results indicate that galectin-3 plays a key role in thymocyte apoptosis and thymic depletion after T. cruzi infection.
Galectin-3 Favors the Escape of Immature Thymocytes from the Thymus
We have previously shown the presence of immature CD4+CD8+ T cells in peripheral lymphoid organs of T. cruzi-infected mice at the peak of parasitemia.7
These immature CD4+CD8+ T cells are thymus-derived because they were absent in peripheral lymphoid organs of infected thymectomized mice.7
To investigate if galectin-3 participates in the premature escape of these cells to the periphery, we compared the presence of immature and mature T-cell subsets in the subcutaneous lymph nodes of gal-3/ and wild-type mice after T. cruzi infection. As expected, an increased number of immature CD4+CD8+ T cells was observed in the subcutaneous lymph nodes of infected wild-type mice (Figure 5)
. Interestingly, this subpopulation was not observed when gal-3/ mice were infected with the parasite (Figure 5)
. These data suggest a putative role for galectin-3 in the exportation of immature CD4+CD8+ double-positive thymocytes to peripheral lymphoid organs secondary to T. cruzi infection.
|
Recently, it was demonstrated that galectin-3 modulates the migration of peripheral blood monocytes/macrophages.30 This effect may be a possible consequence of the deadhesive property of galectin-3. Thus, in an attempt to explain the involvement of galectin-3 with the premature escape of immature CD4+CD8+ thymocytes to peripheral lymphoid organs secondary to T. cruzi infection, we decided to analyze thymocyte capability to migrate using different experimental models.
Initially, we evaluated the effects of galectin-1 and -3 on the migratory response of thymocytes toward laminin. Thymocytes from both control and infected mice were assayed for migration using transwell chambers containing polycarbonate filters coated with laminin-1. Thymocytes were preincubated with either galectin-1 or -3 in the presence or absence of lactose. When thymocytes from control and infected mice were treated with galectin-1, these cells aggregated and adhered to laminin, inhibiting the cell migration (data not shown). In contrast, galectin-3 enhanced migration of thymocytes toward laminin by as much as 10-fold (Figure 6A)
. The effect of galectin-3 on thymocytes obtained from infected animals was even more pronounced (Figure 6A)
. In both cases, galectin-3-induced migration was inhibited by the addition of 0.1 mol/L lactose.
|
We have previously demonstrated that galectin-3 acts as a deadhesion molecule by disrupting thymocyte adhesion to thymic epithelial cells.15
In cultured TNCs, we observed that both galectin-3 and laminin were found in regions of interactions between thymocytes and TECs (Figure 7A)
. This overlap was present in TNCs obtained from infected mice, but, as shown in Figure 7B
, galectin-3 was involving the thymocytes, suggesting its participation in thymocyte exit from these cells. The dynamics of thymocyte release from TNCs may be modulated by exogenous factors, including ECM proteins and antibodies recognizing either ECM or their receptors.28,31
We have exploited this model to determine whether galectin-3 could modulate thymocyte-TEC interactions within the TNCs. Lymphoepithelial complexes obtained from either control or infected mice were cultured and exposed to specific stimuli for 12 hours. Then, cells were fixed, and thymocyte release was assessed by toluidine blue staining. Absorbance was significantly higher for control TNCs than for TNCs from infected animals, indicating that thymocyte release was faster in infected mice. This result was confirmed by direct counting of cells remaining in the TNCs (data not shown). Addition of exogenous galectin-3 resulted in increased levels of thymocyte release, as determined by the lower absorbance. Lactose, which inhibits the lectin activity of galectin-3, but not melibiose, which does not bind galectin-3, was capable of blocking galectin-3-mediated thymocyte release, indicating that exogenous galectin-3 exerts its modulatory effect through protein-glycan interactions (Figure 7C)
. Interestingly, spontaneous thymocyte release from TNCs isolated from gal-3/ mice was significantly slower than in wild-type mice (D.M.S. Villa-Verde, R.F. Schneider, R.F. Samico, E. Silva-Monteiro, W. Savino, unpublished observations).
|
| Discussion |
|---|
|
|
|---|
Previous observations demonstrated the presence of galectin-1 and -3 in the normal mouse thymus.12,13,15 After T. cruzi infection, there is an accumulation of galectin-3 (but not galectin-1) in both cortical and medullary regions of the thymus. Northern blot analysis showed that galectin-3 accumulation was associated with de novo expression of this protein; we observed a 10-fold increase in the relative amount of galectin-3 mRNA in thymuses from infected mice, whereas galectin-1 expression decreased.
We report here that galectin-3 is mainly found in the medulla and in scattered cells in the cortex. On T. cruzi infection, we found a marked increase of galectin-3 immunoreactivity in both cortical and medullary compartments. Thymocytes harvested from both normal and infected mice displayed galectin-3 on the cell surface. More interestingly, thymocytes from infected animals expressed high levels of galectin-3 mRNA. Thus, not only TECs, but also thymocytes, show increased galectin-3 expression under specific conditions, such as T. cruzi infection. It is remarkable that most of the cell surface galectin-3-positive cells corresponded to the CD4+CD8+ double-positive thymocytes. This result was confirmed using an engineered probe that allowed the in situ identification of cells bearing galectin-3 ligands (F.H.M. Melo and R. Chammas, unpublished observations). Interestingly, increased galectin-3 expression was also observed on B cells from T. cruzi-infected mice, and this expression correlated with the ability of this protein to favor a memory B-cell phenotype.33
Two models of thymic epithelial cells, the IT-76M1 TEC line34-36 and primary cultures of the TNCs,25 were used in this study to examine galectin accumulation on infection with T. cruzi. In both cases, galectin-3 (but not galectin-1) accumulated after exposure to the parasite. The consistent accumulation of galectin-3 in the thymus of infected animals together with our previous observations that galectin-3 may act as a deadhesion molecule within the thymic microenvironment,15 prompted us to investigate the potential role of this carbohydrate-binding protein in thymocyte cortical depletion in T. cruzi-infected mice.
Here we provide evidence showing that galectin-3 induces a thymocyte migratory response toward laminin and that this response is even greater in thymocytes from T. cruzi-infected mice. In addition, this molecule is involved in the premature exit of immature CD4+CD8+ double-positive T cells to peripheral lymphoid organs. Further, prolonged exposure of thymocytes to galectin-3 results in extensive cell death. These should be discussed in terms of the differential effects of intracellular and extracellular galectin-3 and the effects of this protein on different cell types. For example, it has been demonstrated that overexpression of galectin-3 in human Jurkat T-cell line and human breast carcinoma cells can protect the cells from apoptosis; in the latter, the effect has been associated with improved cell adhesion properties.37 In addition, galectin-3 can act as an adhesion molecule during neutrophil extravasation in response to infection.38
The mechanisms leading to severe thymic atrophy with massive thymocyte death in acutely T. cruzi-infected animals are not completely understood. We have previously shown that thymic atrophy was not dependent on high levels of glucocorticoids because this effect was still observed in adrenalectomized mice.39 More recently, we demonstrated that it was not dependent on the Fas or perforin cell death pathways because a massive thymocyte loss occurred in T. cruzi-infected Fas-L or perforin-null mice.40 Furthermore, a recent study suggested a role for extracellular ATP in triggering thymocyte death after T. cruzi infection because this molecule induced an increase in plasma membrane permeabilization and cell death in CD4+CD8+ double-positive thymocytes from infected mice during thymic atrophy.41 Interestingly, in the specific TNCs niche, cell death secondary to T. cruzi infection was found to be associated with the effects of a T. cruzi transialidase, which regulates sialic acid mobilization.42 The preferential binding of galectin-3 to thymocyte subsets seems to be also involved in this event. In this regard, the fact that galectin-3 binds preferentially to CD4+CD8+ thymocytes might explain the depletion of cortical cells in wild-type mice. This is consistent with data obtained from gal-3/ mice. These animals did not show a significant thymic atrophy after acute infection or changes in the percentage of CD4+CD8+ double-positive thymocytes. Moreover, because galectin-3 also favors thymocyte migration, it is likely that a small fraction of thymocyte depletion after infection may be attributable to an increased number of cells leaving this organ. Thus, it is conceivable that galectin-3 might not only disrupt thymocyte adhesion but also be responsible for promoting a migratory phenotype. In addition, this protein can trigger high levels of thymocyte apoptosis. In this regard, prolonged exposure to galectin-3 would dictate a run-or-die sentence, unless cells homed into a galectin-3-deprived microenvironment. Although the fate of the immature thymocytes that escape to the periphery is still primarily unknown, it seems likely that some T cells with prohibited TCRs would survive and might be involved in the pathogenesis of autoimmune-related lesions such as those found in Chagas disease.9
In summary, our observations provide evidence of novel extracellular functions for galectin-3, including regulation of thymocyte death and modulation of thymocyte migration. These regulatory functions are clearly involved in thymic atrophy after acute T. cruzi infection. Taken together, our data provide important clues for a better understanding of the pathophysiology of experimental Chagas disease, with potential implications for the future development of novel therapeutic strategies.
| Footnotes |
|---|
Supported in part by The Oswaldo Cruz Foundation, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, and Fundação de Amparo a Pesquisa do Estado de São Paulo.
Supplemental material for this article can be found on http://ajp.amjpathol.org.
Current addresses of E.S.-M.: Department of Pathology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro; and Bioinformatics Laboratory, National Laboratory of Scientific Computation, Petrópolis, Brazil.
Accepted for publication October 27, 2006.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
F. H.M. de Melo, D. Butera, R. S. Medeiros, L. N. d. S. Andrade, S. Nonogaki, F. A. Soares, R. A. Alvarez, A. M. Moura da Silva, and R. Chammas Biological Applications of a Chimeric Probe for the Assessment of Galectin-3 Ligands J. Histochem. Cytochem., October 1, 2007; 55(10): 1015 - 1026. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |